Followers | 42 |
Posts | 5751 |
Boards Moderated | 0 |
Alias Born | 04/12/2021 |
Tuesday, December 27, 2022 9:26:14 PM
HC Wainwright Says Talaris' Technology Unprecedented In Cell Therapy Space
Mentioned: TALS
HC Wainwright initiated coverage on Talaris Therapeutics Inc (NASDAQ: TALS) with a Buy rating and a price target of $18.
Talaris leverages its novel 'facilitated' allogeneic hematopoietic stem cell (Allo-HSCT) transplantation platform for solid organ transplantation, autoimmune diseases, and severe blood, immune and metabolic disorders.
The facilitated Allo-HSCT attempts to unify two immune systems into one (chimerism) such that both the donor and recipient immune cells function harmoniously in the recipient.
Earlier today, Talaris received a report of a patient death, which triggered a pre-specified, temporary stopping requirement and review by the FREEDOM-1 Data Monitoring Committee (DMC).
The analyst views the attributes of Talaris' technology as unprecedented in the cell therapy space and holding potential for broad market adoption in kidney transplants and other indications.
If approved by the end of 2026, HC Wainwright expects FCR001 could achieve over $1 billion in sales in the U.S. by 2030, with significant room for upside growth in the succeeding years.
The analyst also notes investor concerns regarding treatment-related GvHD incidence and writes that physicians perceive mild Grade 2 GvHD as a recurring event in kidney transplant patients.
Price Action: TALS shares are down 44.63% at $1.34 on the last check Thursday.
Latest Ratings for TALS DateFirmActionFromTo
Nov 2021SVB LeerinkMaintainsOutperform Jun 2021Morgan StanleyInitiates Coverage OnOverweight Jun 2021GuggenheimInitiates Coverage OnBuy
View More Analyst Ratings for TALS
View the Latest Analyst Ratings
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.”
my posts are always theory and not financial advice
Recent TALS News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/27/2024 12:12:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/27/2024 12:09:06 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/19/2024 08:05:48 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/19/2024 08:04:57 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/19/2024 08:02:39 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/19/2024 09:10:03 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/19/2024 09:02:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/19/2024 11:09:49 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/20/2023 11:15:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/20/2023 11:14:25 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 11/06/2023 09:30:06 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 10/30/2023 08:15:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2023 09:17:56 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 10/27/2023 08:02:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 09:34:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 09:00:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:46:06 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 10/21/2023 01:23:23 AM
- Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio • GlobeNewswire Inc. • 10/17/2023 09:47:44 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 10/10/2023 08:32:57 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 10/10/2023 08:30:55 PM
- Stocks to Watch: Shift Technologies, Talaris Therapeutics, Lockheed Martin • Dow Jones News • 10/07/2023 12:01:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/06/2023 09:30:59 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 10/06/2023 09:27:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/06/2023 09:26:59 PM
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM